The Healthcare ETF Showdown: Broad Global Health or Targeted Pharma Power?
PJP delivered 32.8% returns over one year with concentrated U.S. pharma exposure, while IXJ offers broader global healthcare diversification and a higher dividend yield.

What's Your Reaction?









